| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Meclocycline Sulfosalicylate targets the bacterial ribosome, specifically the 30S and 50S ribosomal subunits. By binding to these subunits, it inhibits bacterial protein synthesis, thereby exerting its antibacterial effects. It is effective against a wide range of Gram-positive and Gram-negative bacteria.
|
|---|---|
| ln Vitro |
In vitro, Meclocycline Sulfosalicylate exhibits broad-spectrum antibacterial activity against various Gram-positive and Gram-negative bacteria. It prevents bacterial growth by binding to the 30S and 50S ribosomal subunits and inhibiting protein synthesis. Its activity is typical of tetracycline antibiotics. Minimum inhibitory concentration (MIC) values would vary depending on the bacterial strain.
|
| ln Vivo |
In vivo, Meclocycline Sulfosalicylate is used topically for the treatment of skin infections and irritations. Its topical application minimizes systemic exposure and reduces the risk of systemic side effects. The compound is not typically used systemically due to its poor absorption and the availability of other tetracycline antibiotics.
|
| Enzyme Assay |
In vitro antibacterial susceptibility testing for Meclocycline Sulfosalicylate is conducted using broth microdilution or agar dilution methods following Clinical and Laboratory Standards Institute (CLSI) guidelines. Bacterial strains are cultured in appropriate media and incubated with serial dilutions of the compound. The minimum inhibitory concentration (MIC) is determined as the lowest concentration that inhibits visible bacterial growth after 18-24 hours of incubation.
|
| Cell Assay |
Cellular assays for Meclocycline Sulfosalicylate are not typically performed, as the compound is an antibacterial agent that targets bacterial ribosomes, not mammalian cells. Cytotoxicity assays may be conducted in mammalian cell lines to assess potential toxicity. Cells are treated with compound concentrations ranging from 1 to 100 µM for 24-72 hours, and cell viability is assessed using MTT assays.
|
| Animal Protocol |
In vivo animal studies for Meclocycline Sulfosalicylate are limited, as the compound is primarily used topically. Topical efficacy studies may be conducted in animal models of skin infection. The compound is applied to infected skin areas, and the reduction in bacterial load and improvement in clinical signs are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Meclocycline Sulfosalicylate are limited. As a topical agent, systemic absorption is minimal. The sulfosalicylate salt form enhances water solubility. The compound has a molecular weight of 695.05. Systemic PK studies are not typically conducted for topical antibiotics.
|
| Toxicity/Toxicokinetics |
Toxicological data for Meclocycline Sulfosalicylate are typical of tetracycline antibiotics. Topical application may cause local irritation or allergic reactions in some individuals. Systemic toxicity is minimal due to poor absorption. It is contraindicated in patients with known hypersensitivity to tetracyclines.
|
| References | |
| Additional Infomation |
See also: Meclocycline Sulfosalicylate (note moved to).
Meclocycline Sulfosalicylate is a tetracycline antibiotic that binds to 30S and 50S ribosomal subunits to inhibit bacterial protein synthesis. It is topically used for skin infections and irritations. It is a sulfosalicylate salt with enhanced water solubility. It is an approved topical antibiotic in some regions. |
| Molecular Formula |
C22H21N2O8CL.C7H6O6S
|
|---|---|
| Molecular Weight |
695.04768
|
| Exact Mass |
694.087
|
| CAS # |
73816-42-9
|
| Related CAS # |
Meclocycline;2013-58-3
|
| PubChem CID |
54676538
|
| Appearance |
Off-white to yellow solid powder
|
| Boiling Point |
716.4ºC at 760 mmHg
|
| Flash Point |
387.1ºC
|
| LogP |
2.333
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
47
|
| Complexity |
1350
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
CN(C)[C@H]1[C@@H]2[C@H]([C@@H]3C(=C)C4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)Cl)O.C1=CC(=C(C=C1S(=O)(=O)O)C(=O)O)O
|
| InChi Key |
WVJKUGVVYXCLFV-CCHMMTNSSA-N
|
| InChi Code |
InChI=1S/C22H21ClN2O8.C7H6O6S/c1-6-9-7(23)4-5-8(26)11(9)16(27)12-10(6)17(28)14-15(25(2)3)18(29)13(21(24)32)20(31)22(14,33)19(12)30;8-6-2-1-4(14(11,12)13)3-5(6)7(9)10/h4-5,10,14-15,17,26-28,31,33H,1H2,2-3H3,(H2,24,32);1-3,8H,(H,9,10)(H,11,12,13)/t10-,14-,15+,17+,22+;/m1./s1
|
| Chemical Name |
(4S,4aR,5S,5aR,12aR)-7-chloro-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;2-hydroxy-5-sulfobenzoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~359.69 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 4.17 mg/mL (6.00 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 41.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 4.17 mg/mL (6.00 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 41.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4387 mL | 7.1937 mL | 14.3875 mL | |
| 5 mM | 0.2877 mL | 1.4387 mL | 2.8775 mL | |
| 10 mM | 0.1439 mL | 0.7194 mL | 1.4387 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
